DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair.
about
Conformation, protein recognition and repair of DNA interstrand and intrastrand cross-links of antitumor trans-[PtCl2(NH3)(thiazole)].Hexammineruthenium(III) ion interactions with Z-DNAThe Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) ProdrugsPotentiating effect of UVA irradiation on anticancer activity of Carboplatin derivatives involving 7-azaindolesRuthenium anticancer compounds: myths and realities of the emerging metal-based drugs.DNA binding properties, histidine interaction and cytotoxicity studies of water soluble ruthenium(ii) terpyridine complexes.Towards Antitumor Active trans-Platinum Compounds.Effects of geometric isomerism and anions on the kinetics and mechanism of the stepwise formation of long-range DNA interstrand cross-links by dinuclear platinum antitumor complexes.Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates.DNA-Destabilizing Agents as an Alternative Approach for Targeting DNA: Mechanisms of Action and Cellular ConsequencesPhotoactive Ruthenium Nitrosyls: Effects of Light and Potential Application as NO Donors.Antitumor carboplatin is more toxic in tumor cells when photoactivated: enhanced DNA binding.Excursions in polynuclear platinum DNA binding.New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA.Oxaliplatin and its enantiomer induce different condensation dynamics of single DNA moleculesReplacement of a thiourea with an amidine group in a monofunctional platinum-acridine antitumor agent. Effect on DNA interactions, DNA adduct recognition and repair.Monofunctional platinum-DNA adducts are strong inhibitors of transcription and substrates for nucleotide excision repair in live mammalian cellsCharacterisation of the DNA sequence specificity, cellular toxicity and cross-linking properties of novel bispyridine-based dinuclear platinum complexes.Micronuclei to detect in vivo chemotherapy damage in a p53 mutated solid tumour.DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy.Interaction of classical platinum agents with the monomeric and dimeric Atox1 proteins: a molecular dynamics simulation study.Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin.Hrq1, a homolog of the human RecQ4 helicase, acts catalytically and structurally to promote genome integrity.A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin.DNA bending and unwinding due to the major 1,2-GG intrastrand cross-link formed by antitumor cis-diamminedichloroplatinum(II) are flanking-base independent.Diazido mixed-amine platinum(IV) anticancer complexes activatable by visible-light form novel DNA adducts.DNA-protein cross-linking by trans-[PtCl(2)(E-iminoether)(2)]. A concept for activation of the trans geometry in platinum antitumor complexesBinding discrimination of MutS to a set of lesions and compound lesions (base damage and mismatch) reveals its potential role as a cisplatin-damaged DNA sensing protein.Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology?Synergistic antitumor effects of combined deguelin and cisplatin treatment in gastric cancer cellsA dual-targeting, apoptosis-inducing organometallic half-sandwich iridium anticancer complex.Different affinity of nuclear factor-kappa B proteins to DNA modified by antitumor cisplatin and its clinically ineffective trans isomer.DNA binding of dinuclear iron(II) metallosupramolecular cylinders. DNA unwinding and sequence preferenceNucleotide Binding Preference of the Monofunctional Platinum Anticancer-Agent Phenanthriplatin.Comment on "Delivering a photosensitive transplatin prodrug to overcome cisplatin drug resistance" by H. Song, W. Li, R. Qi, L. Yan, X. Jing, M. Zheng and H. Xiao, Chem. Commun., 2015, 51, 11493.Effects of monofunctional adducts of platinum(II) complexes on thermodynamic stability and energetics of DNA duplexes.Conformation of DNA GG intrastrand cross-link of antitumor oxaliplatin and its enantiomeric analog.Chiral differentiation of DNA adducts formed by enantiomeric analogues of antitumor cisplatin is sequence-dependent.Inhibition of nuclear factor kappaB proteins-platinated DNA interactions correlates with cytotoxic effectiveness of the platinum complexes.Ataxia telangiectasia and rad3-related kinase contributes to cell cycle arrest and survival after cisplatin but not oxaliplatin.
P2860
Q24813746-5CF4F62E-17B5-429F-9540-8579058DE2A3Q27649346-B349C83E-3DE4-482B-ACA2-4905966E405DQ28066801-21E36BB0-AC4F-4161-8095-F7ED8DD42321Q28546440-201553C3-74B6-4E3C-A3A7-6AE24EE9FA59Q30403317-A784F1D6-7D85-4766-B555-FA1D12ABD837Q31043552-F8AA97A9-1C38-4AAD-806B-2A72A1B20EC3Q33649706-723AC46C-1681-4D1D-9D1D-AF0289BD8B7AQ33675696-22C7FBEE-5FB0-43FE-A58B-D797797E4F9FQ33808096-57A5E041-E149-43FF-9142-24AB4D9CA519Q34042848-D7058141-8E3F-4742-93F2-4A637822D7D4Q34259551-226602B1-8962-4C93-B2E6-0EAD3B99D8F6Q34283782-1EBBB2B7-B91F-4EB7-BD3D-006EED217ED1Q34480028-C1B607E7-3042-4640-A460-27751C0A2B3BQ34914365-282B3D0E-0ECF-4793-AF63-426983669473Q34949875-9A2795DB-C4D1-4D35-84B9-15F0C107087DQ35257063-1105372A-A89A-49AE-9173-540D6307183BQ35729416-E9BB9234-1711-4A9D-BCB6-7C6825E2C8C6Q36029514-E07DE26F-8401-4B7F-974B-7B049A59D127Q36648259-ED6E9CCB-9A6C-4F51-94A4-E1CC60389CD2Q36910455-D11D9CE1-6C6F-412A-88FF-4E0F550C8690Q37535399-590DCB09-C60B-460A-BCC5-B143ED98B277Q37592356-1BBE4988-EA0C-4FC7-9412-5C7FE1BE23D7Q37600384-A723BA3C-A880-460F-B25C-3DCE3D699B4DQ37709331-DA008D32-9007-442B-8162-4BEF6FC2D496Q38287679-C554719E-970B-47AE-B04D-0DF6637C55BDQ38315077-1641403A-6C14-46C8-BAEF-AF75CB085902Q38348382-3E2B62F9-BF55-4D17-A488-76340CA40F38Q38356417-56134A72-EE7B-4B41-AA10-48AF61A6B1C3Q38710506-A307135A-B255-4587-B418-E43D2345C77FQ38958264-F513025A-D139-488F-A48B-46DBE1599A32Q38994934-02146C15-ADAC-4A8C-8A31-301B33353896Q39034883-A8161F07-BC87-432A-8B6F-DA5D275330BFQ39634241-3E888E41-020C-4D85-B8E1-47B600400A1CQ39824889-F4B1CED3-226B-4E4F-AA28-A84373ECBD0AQ39978440-8899F087-3426-4089-B5E4-0F13A3C395F5Q40316071-753C5988-D1A7-41C9-8EBD-4E4628E0B34BQ40320273-2C942179-E22B-455B-A5E7-407D4A32577EQ40335117-EDA2B736-B3BC-4837-8FB9-6ED5F44D235DQ40971423-D00971BF-DF27-4229-9469-AE5EA501C646Q41785468-A4C7EC75-F9B2-411E-AE0D-7071E5D644FD
P2860
DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
DNA modifications by antitumor ...... their recognition and repair.
@ast
DNA modifications by antitumor ...... their recognition and repair.
@en
DNA modifications by antitumor ...... their recognition and repair.
@nl
type
label
DNA modifications by antitumor ...... their recognition and repair.
@ast
DNA modifications by antitumor ...... their recognition and repair.
@en
DNA modifications by antitumor ...... their recognition and repair.
@nl
prefLabel
DNA modifications by antitumor ...... their recognition and repair.
@ast
DNA modifications by antitumor ...... their recognition and repair.
@en
DNA modifications by antitumor ...... their recognition and repair.
@nl
P1476
DNA modifications by antitumor ...... : their recognition and repair
@en
P2093
Viktor Brabec
P356
10.1016/S0079-6603(02)71040-4
P577
2002-01-01T00:00:00Z